Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
复制标题
DOI：
10.1136/bmj.38793.468449.ae
复制
发表时间：
2006-05-13
影响因子：
105.7
通讯作者：
Carneiro, Antnio Vaz
中科院分区：
文献类型：
--
作者：
Costa, Joao;Borges, Margarida;Carneiro, Antnio Vaz
目的评价降脂药物在糖尿病患者和非糖尿病患者中的临床疗效，对糖尿病患者进行一级预防和二级预防。设计系统综述和荟萃分析。资料来源：Cochrane、Medline、Embase和截至2004年4月的参考文献。研究选择随机、安慰剂对照、双盲试验，评价糖尿病患者和非糖尿病患者的降脂药物治疗。主要结果是主要的冠状动脉事件，定义为冠心病死亡、非致命性心肌梗死或心肌血管重建术。降脂药物治疗在糖尿病患者中至少与非糖尿病患者一样有效。在一级预防中，主要冠状动脉事件的风险降低了21%(95%可信区间为11%~30%；P
Objective To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention.Design Systematic review and meta-analysis.Data sources Cochrane, Medline, Embase, and reference lists up to April 2004.Study selection Randomised, placebo controlled, double blind trials with a follow-up of at least three years that evaluated lipid lowering drug treatment in patients with and without diabetes mellitus.Data extraction Two independent reviewers extracted data. The primary outcome was major coronary events defined as coronary heart disease death, non-fatal myocardial infarction, or myocardial revascularisation procedures.Results Twelve studies were included. Lipid lowering drug treatment was found to be at least as effective in diabetic patients as in non-diabetic patients. In primary prevention, the risk reduction for major coronary events was 21% (95% confidence interval 11% to 30%; P